Importer of Controlled Substances Application: Bellwyck Clinical Services, 27633-27634 [2018-12682]

Download as PDF 27633 Federal Register / Vol. 83, No. 114 / Wednesday, June 13, 2018 / Notices Dated: May 30, 2018. John J. Martin, Assistant Administrator. [FR Doc. 2018–12670 Filed 6–12–18; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration [Docket No. DEA–392] Importer of Controlled Substances Application: Cambrex Charles City ACTION: Notice of application. Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before July 13, 2018. Such persons may also file a written request for a DATES: hearing on the application on or before July 13, 2018. ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DRW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for hearing must be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All request for hearing should also be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/LJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DRW, 8701 Morrissette Drive, Springfield, Virginia 22152. SUPPLEMENTARY INFORMATION: The Attorney General has delegated his authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been delegated to the Assistant Administrator of the DEA Diversion Control Division (‘‘Assistant Administrator’’) pursuant to section 7 of 28 CFR part 0, appendix to subpart R. In accordance with 21 CFR 1301.34(a), this is notice that on March 10, 2018, Cambrex Charles City, 1205 11th Street, Charles City, IA 50616 applied to be registered as an importer of the following basic classes of controlled substances: Controlled substance Drug code 4-Anilino-N-phenethyl-4-piperidine (ANPP) ..................................................................................................................... Phenylacetone ................................................................................................................................................................. Coca Leaves .................................................................................................................................................................... Opium, raw ...................................................................................................................................................................... Poppy Straw Concentrate ............................................................................................................................................... The company plans to import the listed controlled substances for internal use, and to manufacture bulk intermediates for sale to its customers. Dated: June 6, 2018. John J. Martin, Assistant Administrator. [FR Doc. 2018–12683 Filed 6–12–18; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration [Docket No. DEA–392] Importer of Controlled Substances Application: Bellwyck Clinical Services ACTION: Notice of application. Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the amozie on DSK3GDR082PROD with NOTICES1 DATES: issuance of the proposed registration on or before July 13, 2018. Such persons may also file a written request for a hearing on the application on or before July 13, 2018. ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DRW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for hearing must be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All request for hearing should also be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/LJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DRW, 8701 Morrissette Drive, Springfield, Virginia 22152. SUPPLEMENTARY INFORMATION: The Attorney General has delegated his Drug code Amphetamine ........................................................................................................................................................ Methylphenidate .................................................................................................................................................... Oxycodone ............................................................................................................................................................ 18:01 Jun 12, 2018 Jkt 244001 PO 00000 Frm 00096 Fmt 4703 8333 8501 9040 9600 9670 Sfmt 4703 II II II II II authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Assistant Administrator of the DEA Diversion Control Division (‘‘Assistant Administrator’’) pursuant to section 7 of 28 CFR part 0, appendix to subpart R. In accordance with 21 CFR 1301.34(a), this is notice that on April 4, 2018, Bellwyck Clinical Services, 8946 Global Way, West Chester, OH 45069 applied to be registered as an importer of the following basic classes of controlled substances: Controlled substance VerDate Sep<11>2014 Schedule E:\FR\FM\13JNN1.SGM 13JNN1 1100 1724 9143 Schedule II II II 27634 Federal Register / Vol. 83, No. 114 / Wednesday, June 13, 2018 / Notices The company plans to import the listed controlled substances in dosage form to conduct clinical trials. Approval of permit applications will occur only when the registrant’s activity is consistent with what is authorized under to 21 U.S.C.952 (a)(2). Authorization will not extend to the import of FDA approved or nonapproved finished dosage forms for commercial sale. Dated: June 6, 2018. John J. Martin, Assistant Administrator. [FR Doc. 2018–12682 Filed 6–12–18; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Dated: June 6, 2018. John J. Martin, Assistant Administrator. Drug Enforcement Administration [Docket No. DEA–392] [FR Doc. 2018–12680 Filed 6–12–18; 8:45 am] Importer of Controlled Substances Application: Restek Corporation ACTION: BILLING CODE 4410–09–P Notice of application. Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before July 13, 2018. Such persons may also file a written request for a hearing on the application on or before July 13, 2018. ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DRW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for hearing must be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All request for hearing should also be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/LJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DRW, 8701 Morrissette Drive, Springfield, Virginia 22152. SUPPLEMENTARY INFORMATION: The Attorney General has delegated his authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in DATES: amozie on DSK3GDR082PROD with NOTICES1 connection with suspension, denial, or revocation of registration) has been redelegated to the Assistant Administrator of the DEA Diversion Control Division (‘‘Assistant Administrator’’) pursuant to section 7 of 28 CFR part 0, appendix to subpart R. In accordance with 21 CFR 1301.34(a), this is notice that on February 20, 2018, Restek Corporation, 110 Benner Cr., Bellefonte, PA 16823 applied to be registered as an importer of the Schedule I controlled substance Tetrahydrocannibinols (7370). The company plans to import the controlled substance in bulk for the manufacture of analytical reference material which, in its final form, is an exempted product. VerDate Sep<11>2014 18:01 Jun 12, 2018 Jkt 244001 NATIONAL FOUNDATION ON THE ARTS AND THE HUMANITIES Meeting of Humanities Panel National Endowment for the Humanities. ACTION: Notice of meeting. AGENCY: The National Endowment for the Humanities will hold six meetings of the Humanities Panel, a federal advisory committee, during July 2018. The purpose of the meetings is for panel review, discussion, evaluation, and recommendation of applications for financial assistance under the National Foundation on the Arts and Humanities Act of 1965. DATES: See SUPPLEMENTARY INFORMATION for meeting dates. The meetings will open at 8:30 a.m. and will adjourn by 5:00 p.m. on the dates specified below. ADDRESSES: The meetings will be held at Constitution Center at 400 7th Street SW, Washington, DC 20506, unless otherwise indicated. FOR FURTHER INFORMATION CONTACT: Elizabeth Voyatzis, Committee Management Officer, 400 7th Street SW, Room 4060, Washington, DC 20506; (202) 606–8322; evoyatzis@neh.gov. SUPPLEMENTARY INFORMATION: Pursuant to section 10(a)(2) of the Federal Advisory Committee Act (5 U.S.C. App.), notice is hereby given of the following meeting: 1. Date: July 24, 2018. This meeting will discuss applications on the topics of American Literature and Studies, the Arts, and Media, for the Awards for SUMMARY: PO 00000 Frm 00097 Fmt 4703 Sfmt 4703 Faculty grant program, submitted to the Division of Research Programs. 2. Date: July 24, 2018. This meeting will discuss applications on the topics of Literature, History, and the Arts, for the NEH-Mellon Fellowships, submitted to the Division of Research Programs. 3. Date: July 25, 2018. This meeting will discuss applications on the topics of Literature, Philosophy, and Religion, for the Awards for Faculty grant program, submitted to the Division of Research Programs. 4. Date: July 26, 2018. This meeting will discuss applications on the topics of History and Politics, for the Awards for Faculty grant program, submitted to the Division of Research Programs. 5. Date: July 26, 2018. This meeting will discuss applications for Fellowships for Advanced Social Science Research on Japan, submitted to the Division of Research Programs. 6. Date: July 27, 2018. This meeting will discuss applications on the topics of American History and Studies, and Social Sciences, for the Awards for Faculty grant program, submitted to the Division of Research Programs. Because these meetings will include review of personal and/or proprietary financial and commercial information given in confidence to the agency by grant applicants, the meetings will be closed to the public pursuant to sections 552b(c)(4) and 552b(c)(6) of Title 5, U.S.C., as amended. I have made this determination pursuant to the authority granted me by the Chairman’s Delegation of Authority to Close Advisory Committee Meetings dated April 15, 2016. Dated: June 7, 2018. Elizabeth Voyatzis, Committee Management Officer. [FR Doc. 2018–12653 Filed 6–12–18; 8:45 am] BILLING CODE 7536–01–P NUCLEAR REGULATORY COMMISSION [Docket Nos. 50–289 and 50–320; NRC– 2018–0115] Exelon Generation Company, LLC; Three Mile Island Nuclear Station, Units 1 and 2; Suspension of Security Measures in an Emergency or During Severe Weather Nuclear Regulatory Commission. ACTION: Exemption; issuance. AGENCY: The U.S. Nuclear Regulatory Commission (NRC) is issuing an exemption from regulatory requirements in response to an August 1, 2017, SUMMARY: E:\FR\FM\13JNN1.SGM 13JNN1

Agencies

[Federal Register Volume 83, Number 114 (Wednesday, June 13, 2018)]
[Notices]
[Pages 27633-27634]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-12682]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-392]


Importer of Controlled Substances Application: Bellwyck Clinical 
Services

ACTION: Notice of application.

-----------------------------------------------------------------------

DATES: Registered bulk manufacturers of the affected basic classes, and 
applicants therefore, may file written comments on or objections to the 
issuance of the proposed registration on or before July 13, 2018. Such 
persons may also file a written request for a hearing on the 
application on or before July 13, 2018.

ADDRESSES: Written comments should be sent to: Drug Enforcement 
Administration, Attention: DEA Federal Register Representative/DRW, 
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for 
hearing must be sent to: Drug Enforcement Administration, Attn: 
Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All 
request for hearing should also be sent to: (1) Drug Enforcement 
Administration, Attn: Hearing Clerk/LJ, 8701 Morrissette Drive, 
Springfield, Virginia 22152; and (2) Drug Enforcement Administration, 
Attn: DEA Federal Register Representative/DRW, 8701 Morrissette Drive, 
Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: The Attorney General has delegated his 
authority under the Controlled Substances Act to the Administrator of 
the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority 
to exercise all necessary functions with respect to the promulgation 
and implementation of 21 CFR part 1301, incident to the registration of 
manufacturers, distributors, dispensers, importers, and exporters of 
controlled substances (other than final orders in connection with 
suspension, denial, or revocation of registration) has been redelegated 
to the Assistant Administrator of the DEA Diversion Control Division 
(``Assistant Administrator'') pursuant to section 7 of 28 CFR part 0, 
appendix to subpart R.
    In accordance with 21 CFR 1301.34(a), this is notice that on April 
4, 2018, Bellwyck Clinical Services, 8946 Global Way, West Chester, OH 
45069 applied to be registered as an importer of the following basic 
classes of controlled substances:

------------------------------------------------------------------------
      Controlled substance          Drug code            Schedule
------------------------------------------------------------------------
Amphetamine....................            1100  II
Methylphenidate................            1724  II
Oxycodone......................            9143  II
------------------------------------------------------------------------


[[Page 27634]]

    The company plans to import the listed controlled substances in 
dosage form to conduct clinical trials.
    Approval of permit applications will occur only when the 
registrant's activity is consistent with what is authorized under to 21 
U.S.C.952 (a)(2).
    Authorization will not extend to the import of FDA approved or non-
approved finished dosage forms for commercial sale.

    Dated: June 6, 2018.
 John J. Martin,
 Assistant Administrator.
[FR Doc. 2018-12682 Filed 6-12-18; 8:45 am]
 BILLING CODE 4410-09-P